Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Products under Development by Stage of Development | 8 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Products under Development by Therapy Area | 9 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Products under Development by Indication | 10 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Products under Development by Companies | 13 | 2 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Products under Development by Universities/Institutes | 15 | 2 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Therapeutics Assessment | 17 | 4 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Companies Involved in Therapeutics Development | 21 | 10 |
| Astellas Pharma Inc. | 21 | 1 |
| Celon Pharma Sp. z o.o. | 22 | 1 |
| Evotec AG | 23 | 1 |
| F. Hoffmann-La Roche Ltd. | 24 | 1 |
| Glenmark Pharmaceuticals Ltd. | 25 | 1 |
| Johnson &Johnson | 26 | 1 |
| Merck &Co., Inc. | 27 | 1 |
| Pfizer Inc. | 28 | 1 |
| Sunovion Pharmaceuticals Inc. | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Drug Profiles | 31 | 16 |
| ADT-048 Drug Profile | 31 | 1 |
| CPL-50003602 Drug Profile | 32 | 1 |
| JNJ-42314415 Drug Profile | 33 | 1 |
| MCI-020 Drug Profile | 34 | 1 |
| PF-02545920 Drug Profile | 35 | 2 |
| PyP-1 Drug Profile | 37 | 1 |
| RG-7203 Drug Profile | 38 | 1 |
| RO-5461861 Drug Profile | 39 | 1 |
| SEP-39 Drug Profile | 40 | 1 |
| Small Molecule to Inhibit PDE10A for Schizophrenia Drug Profile | 41 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 42 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 43 | 1 |
| TAK-063 Drug Profile | 44 | 2 |
| THPP-1 Drug Profile | 46 | 1 |
| cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) Dormant Projects | 47 | 1 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |